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Abstract
Introduction: Severe sepsis is characterized by an initial hyper-inflammatory response that may progress to an
immune-suppressed state associated with increased susceptibility to nosocomial infection. Analysis of samples
obtained from patients who died of sepsis has identified expression of specific inhibitory receptors expressed on
lymphocytes that are associated with cell exhaustion. The objective of this study was to prospectively determine
the pattern of expression of these receptors and immune cell function in patients with acute sepsis.
Methods: Twenty-four patients with severe sepsis were enrolled within 24 hours of the onset of sepsis, as were 12
age-matched healthy controls. Peripheral blood was obtained at enrollment and again seven days later. Immune
cell subsets and receptor expression were extensively characterized by quantitative flow cytometry. Lymphocyte
function was assayed by stimulated cytokine secretion and proliferation assays. Results were also correlated to
clinical outcome.
Results: At the onset of severe sepsis, patients had decreased circulating innate and adaptive immune cells and
elevated lymphocyte expression of receptors associated with cell activation compared to controls. Samples
analyzed seven days later demonstrated increased expression of the inhibitory receptors CTLA4, TIM-3 and LAG-3
on T lymphocytes accompanied by decreased expression of the IL-7 receptor. Functional assays revealed impaired
secretion of interferon g following stimulation in vitro, which was reversible by incubation overnight in fresh media.
Impaired secretion of IFNg correlated with death or development of secondary infection.
Conclusions: Lymphocytes from patients with acute sepsis upregulate expression of receptors associated with cell
exhaustion, which may contribute to the immune suppressed state that occurs in protracted disease. Therapy that
reverses T cell exhaustion may restore immune function in immunocompromised patients and improve survival in
sepsis.
Introduction
Sepsis is characterized by an intense systemic response
to infection in which patients typically present with
marked respiratory and hemodynamic instability [1].
The initial phase of sepsis is thought in large part to be
result of a ‘cytokine storm’ caused by the activation of
innate and adaptive immune cells and the systemic
release of pro-inflammatory mediators [2,3]. While some
patients rapidly recover, others have a more protracted
course characterized by multiple organ dysfunction syn-
drome (MODS). Many patients with sepsis develop
secondary bacterial infections and these may be caused
by strains that are relatively non-pathogenic in normal
hosts [4]. In addition, patients with sepsis frequently
reactivate latent viruses such as herpes simplex virus
(HSV) or cytomegalovirus (CMV) [5,6]. These observa-
tions have suggested that a subset of individuals with
sepsis enter a more immune suppressed state.
During acute sepsis, the release of pro-inflammatory
cytokines, such as IL-1b and IL-6, and the immune modu-
latory cytokine, IL-10, by innate immune cells such as
macrophages, granulocytes and natural killer (NK) cells
has been well documented (reviewed in [2]). This initial
phase appears to be followed by a rapid induction of apop-
tosis of both innate and adaptive immune cells in a cas-
pase-dependent manner [7-10]. Furthermore, a consistent
decrease in HLA-DR expression, an essential molecule for
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antigen presentation, and expression of co-stimulatory
molecules such as CD86 has also been observed [11-13].
This initial phase of activation and apoptosis may be
accompanied by increased numbers of suppressor cells,
such as regulatory T cells (Treg), myeloid derived suppres-
sor cells (MDSCs) and the recently described CD11b
+/CD62L+ population of granulocytes, as a mechanism
for controlling the adaptive immune response and return-
ing the body to homeostasis [14-19].
We recently published an analysis of tissues obtained
by rapid bedside autopsy from a series of patients who
died as a consequence of sepsis and found a cellular phe-
notype consistent with immune exhaustion [20]. This
phenotype was originally described in the mouse lympho-
choriomeningitis virus (LCMV) model and has been sub-
sequently identified in chronic viral infections in humans
including HIV and chronic hepatitis C infection [21-24].
Exhausted T cells fail to secrete cytokines, have reduced
proliferation in response to antigen and express certain
cell surface receptors (that is, TIM-3, LAG-3, CD69,
cytotoxic T lymphocyte antigen-4 (CTLA-4) and PD-1)
while also decreasing the expression of the IL-7R on their
cell surface [25,26]. Experimental data suggest that T cell
exhaustion may be reversible by interfering with signaling
through inhibitory receptors such as PD-1 [24,27-30].
Thus, if this is an important mechanism of immune-
suppression in sepsis, there may be opportunities to
intervene therapeutically.
By virtue of the study design, there were several impor-
tant limitations of the post-mortem study. Only those
patients who died during the course of their illness were
included, consequently we were unable to determine if the
phenotype was present in all patients with sepsis or only
in those who succumbed from the disease. As samples
were obtained at only a single time point (death) we were
unable to determine changes that occurred during the
course of illness. Furthermore, it is possible that the phe-
notype was present at the outset or even prior to sepsis,
and in fact only identifies those already immune-
suppressed and therefore at higher risk of death should
they become septic.
To address these questions and determine which, if
any, of our findings might be present in living patients
with sepsis, we performed a prospective observational
trial. Patients admitted to the intensive care unit within
24 hours of the onset of severe sepsis were identified and
enrolled. Peripheral blood was obtained at the start of the
study (day 0) and then again at day seven. Immune cells
were isolated from the blood and extensively character-
ized for their expression of activating and inhibitory
receptors as well as for immune function following in
vitro stimulation. Data were then correlated to clinical
outcome, namely development of a secondary infection
or death. Control samples were obtained from age- and
sex-matched healthy volunteers to determine the normal
variance in expression patterns of these receptors. We
determined that in comparison to control subjects, there
were differences in immune cell populations in the blood
and that over time, patients with sepsis had increased
expression of specific inhibitory receptors and ligands on
T cells and antigen presenting cells. In addition, we iden-
tified both immune cell phenotypes and functions that
correlated with the development of secondary infection
and/or death.
Materials and methods
Patients and controls
Patients older than 18 years of age admitted to the medi-
cal or surgical ICU at Barnes-Jewish Hospital with a diag-
nosis of sepsis were identified. Severe sepsis was defined
using a consensus panel definition of the presence of sys-
temic inflammatory response syndrome (SIRS) criteria,
known or suspected source of infection and organ failure
[31]. All patients had respiratory failure requiring
mechanical ventilation on enrollment. Patients with
active malignancy, HIV infection, chronic Hepatitis B or
C infection or on immunosuppressive medications
(except corticosteroids at a dose of < 10 mg prednisone
or equivalent per day) were excluded. Consent was
obtained from the patients legally authorized representa-
tive, as all patients enrolled were judged too acutely ill to
provide valid consent. Onset of severe sepsis, defined by
the time at which the subject met consensus criteria for
severe sepsis was confirmed by the study physician to be
within 24 hours of enrollment. Control subjects consisted
of normal age-matched volunteers with no significant
concomitant acute or chronic illnesses. Clinical data on
the septic patients was captured daily. Patients were
monitored daily for evidence of new infection, and con-
sidered to have developed a secondary infection if there
were new positive cultures and/or clinical data such as
new fever, elevated white blood cells (WBC) and new
infiltrate on chest X-ray consistent with new infection.
All protocols were approved by the Washington Univer-
sity Institutional Review Board.
Sample collection and processing
Heparinized blood was collected through an indwelling
central venous catheter, arterial line or venipuncture
(septic patients) or by peripheral venipuncture (controls)
on day 0 and again at the end of the study (day seven
unless otherwise indicated). The blood was immediately
transported and processed in the research laboratory.
Peripheral blood mononuclear cells (PBMC) were iso-
lated by ficoll-hypaque density gradient separation, using
standard protocols. Plasma was collected and stored at
-80°C for cytokine determinations. The cells were washed
and resuspended in T cell media (Roswell Park Memorial
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Institute (RPMI) 1640 supplemented with 10% heat-inac-
tivated FCS, hydroxyethyl piperazineethanesulfonic acid
(HEPES), penicillin/streptomycin, L-glutamine and non-
essential amino acids) and processed for staining, prolif-
eration or cytokine secretion as described below.
Flow Cytometry
All antibodies were purchased from BD Biosciences (San
Diego, CA, USA), eBiosciences (San Diego, CA, USA) or
Biolegend (San Diego, CA, USA). For surface marker
staining 100 μl of whole blood was incubated with 10 μl
human AB serum and the indicated fluorescently conju-
gated antibodies for one hour at room temperature fol-
lowed by hypotonic red blood cell lysis. The cells were
extensively washed in PBS containing 1% BSA and then
resuspended in PBS containing 1% BSA and 1% parafor-
maldehyde (PFA). For intracellular staining of FoxP3, fol-
lowing surface staining with a-CD4 and a-CD25, cells
were permeabilized with Fix/Perm buffer (eBiosciences)
and incubated with either control or a-FoxP3 antibody
for one hour at 4°C, washed then resuspended in PBS/
BSA containing 1% PFA. Viable lymphocytes were identi-
fied by forward scatter (FSC) and side scatter (SSC) prop-
erties and exclusion of 7-aminoactinomycin D (7-AAD).
T cells were identified as either CD4+ or CD8+. Regula-
tory T cells were identified as CD4+ and CD25+ that co-
labeled with FoxP3. NK cells were identified as CD56+
while natural killer T (NKT) cells co-labeled with CD3
and CD8+ NK cells co-labeled with CD8. Dendritic cells
were identified as lineage cocktail negative (CD3/CD19/
CD16/CD14/CD20/CD56), HLA-DR+ and sub-typed as
plasmacytoid dendritic cells (pDC, CD123+) or monocy-
toid dendritic cells (mDC, CD11c+). MDSC were identi-
fied as lineage cocktail negative, HLA-DR low/negative,
CD33+ and CD11b+. All samples were analyzed by flow
cytometry on a FACSCalibur cytometer (Becton Dickin-
son Corp., Mountainview, CA, USA). Data were further
analyzed using WinList Software (Verity Corporation,
Topsham, ME, USA).
Proliferation and cytokine analysis
PBMCs were resuspended in T cell media at 2 × 106 cells/
ml and 50 μl added to each well of a round bottom
96-well tissue culture plate. The cells were either left
unstimulated or treated with a-CD3 (1 μg/ml, OKT3,
eBiosciences) in combination with a-CD28 (1 μg/ml,
clone CD28.2, eBiosciences) or with phorbol myristate
acetate (PMA) (5 ng/ml) plus ionmycin (0.4 μg/ml). After
48 hours, 1 μCi of tritiated thymidine (3H-TdR) was added
to each well and allowed to incubate overnight. Cells were
harvested onto glass microfiber filters and counts of incor-
porated 3H-TdR determined by liquid scintillography. For
determination of cytokine production, cells were cultured
as described for proliferation and culture supernatant
obtained at five hours and 48 hours following stimulation.
Levels of cytokine present in plasma and culture superna-
tants were determined using the cytokine bead array (BD
Biosciences) according to the manufacturer’s protocol
using the human Th1/Th2/Th17 kit that measures IL-2,
IL-4, IL-6, IL-10, IL-17A, TNF-a and IFNg. For some sam-
ples, the cells were allowed to rest overnight in fresh
media, then stimulated as above and culture supernatant
collected after five hours for cytokine determinations.
Data analysis and statistics
To objectively quantify the per cell expression level of
each receptor, fluorescein isothiocyanate (FITC) and
phycoerythrin (PE). Quantum MESF beads (Bangs
Laboratories, Fishers, IN, USA) were run with each flow
cytometric aassay. The Quantum beads are microspheres,
each of a fixed fluorescence, which when run on a flow
cytometer provide individual peaks (six peaks for FITC
and five peaks for PE) of fluorescence. These peaks of
known fluorescence intensities are converted to Mole-
cules of Equivalent Soluble Fluorochrome (MESF) units,
using a proprietary spreadsheet provided by Bang
Laboratories, Inc., generating a standard curve. The
mean fluorescence intensity (MFI) of each marker is than
converted to MESF units based on the Quantum Bead
MESF standard curve. As the Quantum MESF beads are
run on the flow cytometer at the same time as the subject
samples using the same instrument and settings, samples
obtained from different subjects and/or at different times
can be directly compared. Statistical significance was
determined as a P value < 0.05 upon either a two-tailed
non-parametric Wilcoxon matched pairs test or a two-
tailed Mann Whitney U test (Prism4, GraphPad Software,
Inc. La Jolla CA).
Results
Patient enrollment and specimen collection
Admissions to the medical and surgical ICU were
screened daily for potential subjects. Those who met
enrollment criteria were identified and their legally author-
ized representative approached to obtain informed con-
sent. Twenty-four subjects were enrolled and initial
samples collected. Of these 24 subjects, second samples
were collected from 16 at day seven while five subjects
died prior to the collection of a second sample. One sub-
ject had the second sample collected on day nine and two
subjects had samples collected immediately prior to the
withdrawal of life-sustaining therapies (on day two and
day five). The clinical characteristics of the septic popula-
tion are shown in Table 1. As expected, the patients were
acutely ill with a median Acute Physiology and Chronic
Health Evaluation II (APACHE II) score of 20 and a mor-
tality of just over 40%. A number of comorbidities were
present as is typical for this patient population. Three
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subjects were on low dose corticosteroids at the time of
enrollment. Control subjects were identified and selected
to approximately age- and sex-match the patient popula-
tion. Only those with no underlying chronic health condi-
tions were included as controls.
Characterization of circulating immune cells at onset of
severe sepsis
At enrollment the median total WBC count was 12,900
cell/μl with an absolute lymphocyte count (ALC) of 971
cells/μl. Half of the subjects were lymphopenic with an
ALC of < 1,000. Over the first week, the ALC increased on
average by 340 cells/μl, but this change was not statisti-
cally significant. To determine the distribution of lympho-
cyte subsets as well as expression of cell surface molecules
on specific cell populations, blood was obtained within
24 hours of the onset of severe sepsis and extensively char-
acterized by flow cytometry (Figures 1 and 2). An identical
analysis was performed on healthy control subjects to
provide a comparison population. The markers used to
identify each cell population are described in the methods.
As shown in Figure 1, there was a reduction in the percen-
tage of CD4+ T cells and a trend towards a decrease in
CD8+ T cells in the blood of acutely septic patients. A cor-
responding decrease in innate immune cells was also
observed in the blood of septic patients with the percen-
tage of NK cells and dendritic cells (both pDC and mDC)
being reduced. Expression of CD86, a ligand for the T cell
costimulatory receptor CD28, was decreased on mDC.
While there was no difference in the percentage of Treg
cells at day 0, there was a trend towards an increase in
CD11b+ myeloid derived suppressor cells, a population
implicated in mediating immune suppression in cancer
and infection [18,19] in acutely septic subjects.
In the acute phase of sepsis, both lymphocyte activa-
tion and depletion has been documented [2,3]. T cells
isolated from the blood of acutely septic individuals also
had elevated expression of CD25, as a percentage of
CD4+ T cells (Figure 1), and of CD69 (Figure 2), as
both a percentage of positive cells and expression level
per CD4+ T cell (MESF), indicative of an activated phe-
notype. Interestingly, we also observed a trend in ele-
vated expression, as determined by MESF (P = 0.07), of
Programmed Death Receptor-1 (PD-1), an important
negative regulator of lymphocyte function, in the septic
individuals compared to healthy subjects. The other
major inhibitory receptors expressed by T cells are
BTLA and CTLA-4. The majority of T cells expressed
BTLA (> 90%) in both septic and non-septic individuals.
There was a higher percentage of CD8+ T cells that
expressed LAG-3 as well as elevated per cell expression
when compared to age-matched healthy individuals. No
other significant differences in CD8+ T cell expression
of either activation or inhibitory receptors were
observed. These data suggest that the observed changes
are specific and not due to non-specific upregulation of
all cell surface receptors.
Changes in receptor expression over the course of acute
sepsis
We hypothesized that specific changes in receptor
expression patterns over the course of acute sepsis
would be detected. In particular, we were interested in
whether receptor ligand pairs that had been implicated
Table 1 Clinical characteristics of patients with sepsis and controls.
Parameters Patients with sepsis (n = 24) Control subjects (n = 12)
Age, median years (range) 62 (29 to 91) 57 (44 to 59)
Males, percentage (number) 54 (13) 42 (5)
APACHEII at admission, median (range) 20 (10 to 33) n/a
MOD score at admission, median (range) 6 (1 to 10) n/a
28-day mortality, percentage (number) 42 (10) n/a
Nosocomial infection, percentage (number) 21 (5) n/a
Length of ICU stay, median days (range) 6.5 (1 to 28) n/a
Length of hospitalization, median days (range) 11.5 (1 to 89) n/a
Ventilation days, median days (range) 4 (1 to 19) n/a
WBC at enrollment, median cells/μL × 10-3 (range) 12.8 (0.4 to 47) n/a
Absolute lymphocyte count, median cells/μl × 10-3 (range) 0.97 (.07 to 4.8) n/a
Comorbidities, percentages none
End stage renal disease 17
Cirrhosis 17
Diabetes 13
Cardiovascular disease 35
APACHEII, Acute Physiology and Chronic Health Evaluation II; MOD, multiple organ disfunction; n, number; WBC, white blood cell
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in inhibiting lymphocyte function were upregulated over
time. Therefore, we repeated the flow cytometric analy-
sis on samples obtained later in the disease. Except as
noted in the methods, the repeat analysis was performed
on day seven for all subjects in whom a second sample
was able to be collected. As presented in Figure 3,
changes in the expression of several receptors were
noted over this time interval. On both CD4+ and CD8+
T cells, we observed a trend towards a decrease in per
cell expression of the IL-7 receptor (CD127) and a
decrease in the overall percentage of CD8+ cells that
expressed the IL-7R. Expression of TIM-3 and LAG-3,
as determined by quantitative MESF values was also
increased on CD4+ T cells. On CD4+ and CD8+ T
cells, we detected an increase in expression of CTLA-4
by MESF as well as an increase in the percentage of
cells expressing CTLA-4. Models of cell exhaustion have
reported persistent elevated expression of the activation
marker CD69. We found that patients with sepsis did
have a higher expression of CD69 on CD4+ T cells at
the onset of sepsis, as well as a higher circulating per-
centage of CD69 expressing CD4+ T cells and this did
not significantly change over the course of the acute ill-
ness (data not shown). The percentage of pDC that
expressed the ligand for PD-1, PD-L1, increased over
the duration of sepsis, as did expression of CD86 on
mDC (Figure 4). Although we did not detect any differ-
ence in the percentage of Treg cells at the onset of sep-
sis, this increased significantly over the interval in septic
patients but not in normal controls (Figure 4). This pat-
tern of increased inhibitory receptor expression is con-
sistent with our findings in patients who died of sepsis,
and is compatible with the phenotype of immune cell
exhaustion. Smaller, but statistically significant changes
in the expression of a few markers were also detected in
control subjects, highlighting the need for caution in
interpreting these results.
We measured the level of a panel of seven circulating
cytokines in the plasma of patients with sepsis and con-
trols. Of those measured, only IL-6 and IL-10 were dif-
ferent with the remaining cytokines being very low or
undetectable in either subject population (Figure 5 and
Additional File 1, Table S1). Both IL-6 and IL-10 were
significantly higher in patients with sepsis and both
decreased markedly from enrollment to the end of the
study. Three of the four patients with the highest IL-6
levels at enrollment died, two during the first week and
one later in the hospitalization. We did not detect any
relationship of IL-10 levels or the IL-6:IL-10 ratio to
clinical outcome (data not shown).
Stimulated PBMC cytokine secretion and proliferation in
patients with sepsis
We had previously reported that PBMCs isolated from
patients who died of sepsis had a profound global reduc-
tion in cytokine secretion when stimulated in vitro [20].
To determine whether the defect was present in patients
with acute sepsis, we performed a similar analysis on
PBMCs isolated at enrollment and at the end of the
study. In contrast to our findings with post-mortem spe-
cimens, in this study we found that cytokine secretion
from PBMCs activated in vitro was largely preserved
with the notable exception of IFNg (Figure 6 and Addi-
tional File 2, Table S2). Secretion of IFNg following 48
hours of stimulation with a-CD3/a-CD28 antibody was
markedly reduced compared to normal controls in sam-
ples obtained at either enrollment or at the end of study
participation.
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Figure 1 Characterization of immune cell subsets at the onset of sepsis. Peripheral blood was collected from patients within 24 hours of
the onset of severe sepsis and from controls and analyzed by flow cytometry to determine the percentage of circulating cells of each subset.
The markers used to identify each subset are described in the methods. Horizontal lines indicate the mean value. P values were calculated by a
non-parametric 2-tailedMann-Whitney U-test.
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Figure 2 Determination of expression pattern of specific receptors on CD4- and CD8-positive T cells at the onset of severe sepsis.
Peripheral blood was collected from patients within 24 hours of the onset of severe sepsis and from normal controls and stained for the
indicated markers. The percent positive relative to isotype control staining was determined. Fluorescence intensity was quantified by calculation
of MESF values as described in the methods. Horizontal lines indicate the mean value. P values were calculated by a non-parametric 2-
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One potential explanation for the observed defect in
IFNg secretion was that factors present or absent in the
septic milieu might reversibly impair cytokine secretion.
To test this, the cells were either stimulated immediately
or rested overnight in fresh media and then stimulated for
five hours with a-CD3/a-CD28. As shown in Figure 6C,
the rested cells from patients with sepsis, but not controls,
had significantly greater secretion of IFNg (rested: 16.1 ±
23.1 pg/ml versus no rest: 5.7 ± 15.7 pg/ml P < 0.01). The
fact that overnight rest in fresh media restored IFNg secre-
tion to levels near those of controls subjects suggests that
the impairment may in fact be reversible, perhaps by
removal of an inhibitory factor or addition of a growth fac-
tor present in fresh media.
As an additional measure of lymphocyte function, we
assessed the proliferative capacity of PBMCs following in
vitro stimulation (Figure 6D). The mean proliferation of
PBMCs stimulated with a-CD3/a-CD28 from septic indi-
viduals was similar to non-septic individuals at enrollment
and at the end of the study. Therefore, although there was
a decrease in IFNg secretion, there is not a global impair-
ment in all cellular functions in this patient population.
Plasma IL-6 and stimulated IFNg secretion correlate with
clinical outcome
We were interested in determining which, if any, of the
immunologic variables measured correlated with a clini-
cally significant outcome. All patients with sepsis were
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Figure 3 Changes in receptor expression on CD4 and CD8 T cells over the course of acute sepsis. Peripheral blood was collected at
enrollment and again seven days later from patients with severe sepsis and from normal controls and analyzed by flow cytometry for the
indicated markers on CD4- and CD8-positive T cells. The lines connect values at enrollment and the end of the study from an individual subject.
Percentages and MESF values were calculated as described in the methods. P values were calculated by 2-tailed, non-parametric Wilcoxin
matched pairs test. MESF, molecules of equivalent soluble fluorochrome.
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Figure 4 Changes in expression of inhibitory and costimulatory ligands on dendritic cell subsets and regulatory T cell percentages
over the course of acute sepsis. Peripheral blood was collected at enrollment and again seven days later from patients with severe sepsis and
from normal controls and analyzed by flow cytometry for the presence of regulatory T cells (Treg) and dendritic cells (DC). The plasmacytoid and
myeloid DC subsets were analyzed for expression of the inhibitory ligand PD-L1 or costimulatory ligand CD86 respectively. The lines connect
values at enrollment and the end of study from an individual subject. Percentage and MESF values were calculated as described. P values were
calculated by 2-tailed, non-parametric Wilcoxin matched pairs test. MESF, molecules of equivalent soluble fluorochrome.
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followed over the course of their hospitalization for
overall mortality or evidence of a new infection. In addi-
tion, we determined if patients were re-admitted within
28 days of the enrollment with a new infection. In the
course of the study ten patients died as a result of their
illness, six patients developed a second infection (two of
whom died. Two infections occurred after discharge and
resulted in readmission within 28 days.) and ten patients
survived without a second infection. We analyzed
whether any parameters we measured at enrollment cor-
related with either second infection and mortality
together or mortality alone. Consistent with previous
reports, patients who died or had second infections had
higher plasma IL-6 levels than those who had an
uneventful recovery (Figure 7A) [32]. Interestingly, those
patients who developed a second infection or died had
significantly less IFNg secretion from in vitro stimulated
PBMCs than those who recovered uneventfully (Figure
7B). These data are supportive of the hypothesis that
functional immune cell impairment may predispose to a
poor outcome.
Discussion
The acute phase of sepsis is characterized immunologi-
cally by activation of the innate immune cells, resulting
in an intense pro-inflammatory state and ‘cytokine
storm’. The initial pro-inflammatory state is countered
by a compensatory anti-inflammatory response, which if
excessive or prolonged may result in a significant ele-
ment of immune suppression [3,33]. Thus, sepsis results
in the activation of essentially all facets of the immune
system. Understanding the temporal changes that occur
in immune cells during the course of sepsis is critical
for determining when the immune response has become
more harmful than helpful, and for designing rational
therapeutic strategies to intervene when necessary.
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We had previously extensively characterized the
immune cells isolated from the spleens and lungs of
patients who had succumbed to severe sepsis [20]. The
results suggested profound immunosuppression in this
population of patients, as evidenced by a failure of lym-
phocytes to secrete cytokines after in vitro stimulation as
well as a pattern of elevated cell surface expression of
inhibitory receptors and ligands. However, the post-mor-
tem study was limited in only analyzing cells obtained at
the time of death. By virtue of its design, that study could
not address whether the phenotype observed was present
at initiation of sepsis or developed over the course of the
disease. In the current study we performed a prospective
analysis of patients with acute sepsis. Immune cell phe-
notype and function were extensively characterized at the
onset of sepsis and then again one week later. Our
findings confirm several important results of the post-
mortem study, and provide additional insights into
immune system function during sepsis. One limitation of
this study is that we only examined a limited number of
patients, thus our results require validation on a larger
sample size. A further limitation of this current study is
that our control population consisted only of normal
healthy individuals and not critically ill non-septic
patients; therefore, any findings in the septic patient
population may be due to acute critical illness or perhaps
even due to underlying co-morbid disease and not neces-
sarily from sepsis per se. However, an important aspect of
this study is the temporal change in immune status. In
this analysis the comparison is to the same subject at
time 0, therefore they serve as their own control. Thus,
independent of the lack of a critically ill control popula-
tion, our findings document the status of the immune
system at the outset of sepsis and the temporal changes
that occur during the disease.
Our findings demonstrated a reduction in circulating
innate (NK and DC) and adaptive (CD4+) immune cells in
samples obtained at enrollment, consistent with reports
demonstrating significant lymphopenia and cell death
early in the course of disease [7-10,34-39]. While cell
death is important, the evolution of the phenotype and
functional status of the remaining cells over the course of
the disease may also be a determinant of the host response
and outcome. Many studies have examined only limited
cell populations and receptors and/or at only a single time
point. A strong association of monocyte HLA-DR expres-
sion with mortality and development of nosocomial infec-
tion in patients with sepsis has been found, demonstrating
the clinical utility and importance of understanding the
status of the immune system during sepsis [12,40,41]. In
the current study, we included an extensive battery of
markers to provide a detailed picture of the lymphocyte
phenotype at the onset and again at a later stage of sepsis.
An important caveat to the interpretation of data from
many previous studies is the lack of a reproducible quanti-
tative methodology for determining the expression levels
of cell surface proteins, limiting the ability to compare spe-
cimens obtained and analyzed at different times in a con-
trolled manner, as discussed in a recent review by Venet et
al. [42]. By incorporating the use of reference fluorescent
beads with each analysis, we were able to standardize
fluorescence measurements to a standard curve and accu-
rately compare measurements between subjects and time
points.
In early sepsis, most markers we examined were not
different from normal controls, with the exception of
increased expression of the early activation marker CD69
and the IL-2 receptor (CD25) on CD4+ T cells and the
inhibitory receptor LAG-3 on CD8+ T cells as well as a
small but statistically significant reduction in CTLA-4
expression. PD-1 expression on CD4+ T cells was some-
what higher than in controls, but did not quite reach sta-
tistical significance (P = 0.07). Over time, we found the
expression of the inhibitory receptor CTLA-4 on both
CD4+ and CD8+ T cells and TIM-3 and LAG-3 on CD4
+ T cells increased on cells from septic patients. Both
CD4+ and CD8+ T cells had decreases in expression of
the receptor for the homeostatic cytokine IL-7 over the
course of the study. We did observe minor changes in
receptor expression patterns in the control patients; how-
ever, these tended to be smaller in magnitude than those
observed in the septic patients and driven by only a few
subjects. Nonetheless, this does suggest that there are
normal variations within an individual over time that
must be accounted for in any analysis of this type.
The change in receptor expression pattern that we
observed over the course of sepsis, increased TIM-3,
LAG-3 and CD69 with decreased IL-7R expression, is
consistent with the phenotype of immune cell exhaus-
tion, although the functional impairment was not as
severe. Best characterized in murine systems, there is a
growing body of evidence that the exhausted phenom-
enon is important in human disease, including chronic
Hepatitis B, Hepatitis C and HIV infection
[24,26,30,43-46]. In HIV, exhausted T cells display ele-
vated levels of PD-1, TIM-3, LAG-3 and CTLA-4 and
treatment with a TIM-3 blocking antibody restored T
cell function [47]. In Hepatitis B and C, interference
with PD-1 restored T cell responses [24,45]. These data
illustrate the importance of understanding the expres-
sion of regulatory receptors on immune cells and the
potential for manipulation of these pathways. Future
studies examining the expression and function of these
inhibitory receptors in patients with sepsis, non-septic
critically ill and other control populations will be of par-
ticular interest.
In addition to changes of receptor expression in the
lymphocyte compartment, myeloid and plasmacytoid
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dendritic cells also displayed temporal changes in the
expression of ligands for costimulatory and inhibitory
receptors. Increased expression of PD-L1 on pDC was
accompanied by an increase in CD86 and a decrease in
CD80 on mDC over the course of the study (Figure 4
and data not shown). These changes are consistent with
murine studies demonstrating an important role for
CD80 and CD86 in the response to sepsis, and with a
reciprocal pattern of regulation of these receptors on
circulating monocytes in humans with sepsis [13,48].
The observation that there is overlapping expression
of activating receptors and ligands on T cells and anti-
gen presenting cells (APCs) is consistent with a model
of immune cell exhaustion occurring over a continuum.
Early in the immune response activating signals predo-
minate, but also induce expression of inhibitory recep-
tors. In the face of ongoing antigen stimulation, there
may be downregulation of activating receptor:ligand
pairs with persistent expression of inhibitory receptors
and ligands. The temporal sequence may differ depend-
ing on many factors including the cell type examined
and the nature of the ongoing stimulus. Thus, depend-
ing on when sampled, the actual expression pattern may
be predominantly one of activating receptors, inhibitory
receptors or both [26,49,50].
Recently, there have been several reports suggesting an
important role for PD-1 in sepsis [51-54]. PD-1 is a
receptor expressed on activated lymphocytes, which
when engaged by its ligands PD-L1/PD-L2, inhibits cell
proliferation and function [55]. In both animal models
and humans, PD-1 has been implicated in the immune
suppression that is often observed in malignancy and in
chronic viral infections. In particular, experimental evi-
dence supports an important role for PD-1 signaling in
contributing to immune cell exhaustion characteristic of
certain chronic viral infections [27,28,56,57]. In experi-
mental murine sepsis, blockade of PD-1 or PD-L1
improved survival and in humans upregulated PD-1
expression has been detected and correlated with worse
outcome [52,53]. In our study, PD-1 expression on CD4
+ T cells was slightly higher than controls at day one,
and although the increase in expression by day seven
was not significant, it was higher than day seven con-
trols, both in the percentage of PD-1 expressing CD4+
T cells (24% versus 15%, P < 0.05) and the MESF (1,413
versus 682, P < 0.005). Concurrently, we detected an
increase in the percentage of pDC that expressed PD-
L1, a ligand for PD-1, from enrollment to the end of the
study in septic patients. Thus, our data provide further
evidence in support of a role for the PD-1/PD-L axis in
sepsis.
Suppressor cell populations have been shown to be
increased in septic individuals [14,17,19,58-61]. These
may be an important mechanism to down-modulate the
inflammatory response but also carry the potential for
deleterious consequences. Although we did not observe
an increase in the percentage of Tregs at day 0 relative
to controls (Figure 4), the percentage increased over the
course of the disease. However, whether this is due to
an expansion of the Treg population or a loss of CD4
+CD25- cells, as has been described, cannot be defini-
tively determined [62]. Myeloid derived suppressor cells,
were noted to be increased at 24 hours in septic
patients, although the level did not quite reach statistical
significance (P = 0.08) and proceeded to return to base-
line levels by day seven in our septic subjects (data not
shown). This provides another potential mechanism
whereby innate cells can inhibit T cell responses early in
the course of the disease until the control systems of the
adaptive immune system (that is, Tregs) become
functional.
Our functional analysis of the immune cells revealed a
relatively selective defect in the secretion of IFNg, with
preserved secretion of other cytokines. While the
impaired IFNg secretion was consistent with our pre-
vious findings, the preservation of other cytokines is
counter. One explanation for this discrepancy may be
that many of these subjects are fundamentally different
than those who died. Death from sepsis is the most
extreme outcome, and it is likely that the organ dysfunc-
tion, including immune cell impairment, is greater in
those who die. In addition, in the post-mortem analysis,
both splenic and lung tissue from septic patients had
aberrant expression of the ligands for inhibitory recep-
tors on antigen presenting and parenchymal cells [20].
The fact that in the current study we did not observe as
severe an impairment of function in circulating cells
suggests that an important mechanism of immunosup-
pression may in fact be local inhibition of lymphocyte
function by engagement of inhibitory receptors by
ligand expressed in the peripheral tissue.
We did observe that the most severe impairment of
IFNg secretion at enrollment was correlated with either
development of secondary infection or death. Thus, this
may be an important marker to identify those at risk.
Furthermore, the reversibility of the impairment in
immune cell function may be an important factor in the
ability of subjects to recover and in developing thera-
peutic approaches to augment immune cell function.
Our data suggest that the impaired function, as mea-
sured by IFNg secretion, may be reversible, as cells first
rested overnight in fresh media had greater cytokine
secretion than cells stimulated immediately on isolation
from the blood. Identification of the factor(s) responsi-
ble for either inhibiting or augmenting T cell function
may provide important mechanistic insights.
As a further assessment of lymphocyte function, we
measured proliferation in response to stimulation with
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a-CD3 and a-CD28. The proliferative capacity was not
decreased relative to controls in specimens obtained
either at enrollment or at the end of the study. Pre-
viously published work has demonstrated reduced prolif-
eration in samples obtained from patients with sepsis
[52]. In that study samples were isolated at day three to
five of sepsis and stimulated with the non-specific mito-
gen, phytohemagglutinin (PHA), whereas we examined
cells either at day one or day seven and activated with
a-CD3/a-CD28 which more selectively induces T cell
proliferation. These experimental differences, as well as
other methodological differences may account for the
discrepancy.
Conclusions
Acute sepsis is characterized by the loss of circulating
innate and adaptive immune cells and impaired secre-
tion of IFNg. Over the first week of illness, patients with
sepsis upregulate the expression of a number of impor-
tant inhibitory receptors and their ligands on the surface
of lymphocytes and dendritic cells, downregulate expres-
sion of the receptor for IL-7 and increase the numbers
of Treg cells. Combined, these changes are consistent
with an early stage of immune cell exhaustion and may
be important in predisposing some patients to nosoco-
mial infection or poor outcome, as well as suggest
further targets for development of treatment interven-
tion strategies.
Key messages
• At the onset of sepsis, while there is evidence of
loss of innate and adaptive immune cells, there are
only minor differences in the expression of inhibi-
tory receptors on circulating lymphocytes.
• Over the first week of acute sepsis, lymphocytes
upregulate specific inhibitory receptors and downre-
gulate the IL-7 receptor, a phenotype associated with
cell exhaustion. Thus, the exhausted phenotype is
not present at the earliest stage of sepsis, but may
develop during the course of the disease.
• Lymphocytes from patients with sepsis have
impaired secretion of IFNg when measured at both
the onset of sepsis and again later in the course of
the disease. This is reversed by overnight rest of the
cells in fresh media prior to stimulation.
• Impaired IFNg secretion correlated with clinically
significant morbidity and mortality.
Additional material
Additional file 1: Supplemental Table 1: Plasma cytokine levels.
Plasma was collected at study enrollment and again at the end of the
protocol. Cytokines were measured by multiplex ELISA (Cytokine Bead
Array, BD Biosciences). Values are reported as pg/ml. The mean ±
standard deviation are shown. P values were calculated using a non-
parametric 2-tailed Mann-Whitney U-test.
Additional file 2: Supplemental Table 2: Stimulated PBMC cytokine
secretion. PBMCs were isolated from patients with sepsis or normal
controls at enrollment and again at the end of the protocol. The cells
were stimulated in vitro with a-CD3 and a-CD28 antibodies for either
five or 48 hours and culture supernatants analyzed for cytokine content
by multiplex ELISA (Cytokine Bead Array, B-D Biosciences). Results shown
are mean ± standard deviation for all subjects and reported as pg/ml. *
= P < 0.05. ** = P < 0.01 by Mann-Whitney test.
Abbreviations
7-AAD: 7-aminoactinomycin D; ALC: absolute lymphocyte count; APACHE II:
Acute Physiology and Chronic Health Evaluation II; BSA: bovine serum
albumin; BTLA: B and T lymphocyte attenuator; CBA: cytokine bead array;
CMV: cytomegalovirus; CTLA-4: cytotoxic T lymphocyte antigen-4; FCS: fetal
calf serum; HCV: hepatitis C virus; HSV: herpes simplex virus; 3H-TdR: tritiated
thymidine; HVEM: herpes viral entry mediator; IFN: interferon; IL: interleukin;
LAG-3: lymphocyte-activation gene 3; LCMV: lymphochoriomeningitis virus;
mDC: myeloid dendritic cell; MDSC: myeloid derived suppressor cell; MESF:
molecules of equivalent soluble fluorochrome units; MFI: mean fluorescence
intensity; MODS: multiple organ dysfunction syndrome; NK: natural killer
cells; NKT: natural killer T cells; PBMC: peripheral blood mononuclear cells;
PBS: phosphate buffered saline; PD-1: programmed cell death receptor -1;
pDC: plasmayctoid dendritic cell; PD-L: programmed death receptor ligand;
PFA: paraformaldehyde; PHA: phytohemagglutinin; PMA: phorbol myristate
acetate; SIRS: systemic inflammatory response syndrome; TIM-3: T cell
immunoglobulin mucin-3; TNF: tumor necrosis factor; Treg: regulatory T cells;
WBC: white blood cell count.
Acknowledgements
The authors thank Christine Deppong, Traci Bricker, Brandy Rannals and Seth
Crockford for advice and technical support of this project. The authors thank
Ann Doyle for patient enrollment and clinical data capture. This project was
funded by grants R21HL104985 (JMG), GM044118 (RSH) and GM055194
9RSH) from the National Institutes of Health. We thank the Center for
Biomedical Informatics (CBMI) for use of ClinPortal and CaTissue. This
publication was made possible through funding support for the CBMI from
the Alvin J. Siteman Cancer Center (SCC) at Washington University School of
Medicine, Barnes-Jewish Hospital in St. Louis, MO and the Institute of Clinical
and Translational Sciences (ICTS) at Washington University in St. Louis. The
SCC is supported in part by the National Institutes of Health’s NCI Cancer
Center Support Grant #P30 CA91842 and the ICTS is funded by the National
Institutes of Health’s NCATS Clinical and Translational Science Award (CTSA)
program (Grant # UL1 RR024992).
Author details
1Department of Internal Medicine, Washington University School of
Medicine, 660 S. Euclid Ave, St Louis, MO 63110, USA. 2Departments of
Anesthesia and Surgery, Washington University School of Medicine, 660 S.
Euclid Ave, St Louis, MO 63110, USA.
Authors’ contributions
JSS screened and enrolled subjects as well as performed most of the assays
reported in this paper. JSB optimized many of the assays, interpreted the
data, prepared figures and wrote sections of the paper. RSH contributed to
the experimental design and interpretation. JMG designed the study,
oversaw all aspects of the study, interpreted the data and prepared final
drafts of all figures as well as wrote the manuscript. All authors reviewed
and approved of the final paper.
Competing interests
The authors declare that they have no financial or non-financial competing
interests.
Received: 13 April 2012 Revised: 14 June 2012 Accepted: 28 June 2012
Published: 28 June 2012
Boomer et al. Critical Care 2012, 16:R112
http://ccforum.com/content/16/3/R112
Page 12 of 14
References
1. Russell JA: Management of Sepsis. New Engl J Med 2006, 355:1699-1713.
2. Cohen J: The immunopathogenesis of sepsis. Nature 2002, 420:885-891.
3. Bone RC, Grodzin CJ, Balk RA: Sepsis: a new hypothesis for pathogenesis
of the disease process. Chest 1997, 112:235-243.
4. Alberti C, Brun-Buisson C, Burchardi H, Martin C, Goodman S, Artigas A,
Sicignano A, Palazzo M, Moreno R, Boulme R, Lepage E, Le Gall R:
Epidemiology of sepsis and infection in ICU patients from an
international multicentre cohort study. Intensive Care Med 2002,
28:108-121.
5. Hotchkiss RS, Coopersmith CM, McDunn JE, Ferguson TA: The sepsis
seesaw: tilting toward immunosuppression. Nat Med 2009, 15:496-497.
6. Limaye AP, Kirby KA, Rubenfeld GD, Leisenring WM, Bulger EM, Neff MJ,
Gibran NS, Huang ML, Santo Hayes TK, Corey L, Boeckh M:
Cytomegalovirus reactivation in critically ill immunocompetent patients.
JAMA 2008, 300:413-422.
7. Hotchkiss RS, Swanson PE, Freeman BD, Tinsley KW, Cobb JP,
Matuschak GM, Buchman TG, Karl IE: Apoptotic cell death in patients with
sepsis, shock, and multiple organ dysfunction. Crit Care Med 1999,
27:1230-1251.
8. Hotchkiss RS, Chang KC, Swanson PE, Tinsley KW, Hui JJ, Klender P,
Xanthoudakis S, Roy S, Black C, Grimm E, Aspiotis R, Han Y, Nicholson DW,
Karl IE: Caspase inhibitors improve survival in sepsis: a critical role of the
lymphocyte. Nat Immunol 2000, 1:496-501.
9. Hotchkiss RS, Tinsley KW, Swanson PE, Schmieg RE Jr, Hui JJ, Chang KC,
Osborne DF, Freeman BD, Cobb JP, Buchman TG, Karl IE: Sepsis-induced
apoptosis causes progressive profound depletion of B and CD4+ T
lymphocytes in humans. J Immunol 2001, 166:6952-6963.
10. Hotchkiss RS, Tinsley KW, Swanson PE, Grayson MH, Osborne DF,
Wagner TH, Cobb JP, Coopersmith C, Karl IE: Depletion of dendritic cells,
but not macrophages, in patients with sepsis. J Immunol 2002,
168:2493-2500.
11. Docke WD, Randow F, Syrbe U, Krausch D, Asadullah K, Reinke P, Volk HD,
Kox W: Monocyte deactivation in septic patients: restoration by IFN-
gamma treatment. Nat Med 1997, 3:678-681.
12. Monneret G, Lepape A, Voirin N, Bohe J, Venet F, Debard AL, Thizy H,
Bienvenu J, Gueyffier F, Vanhems P: Persisting low monocyte human
leukocyte antigen-DR expression predicts mortality in septic shock.
Intensive Care Med 2006, 32:1175-1183.
13. Nolan A, Kobayashi H, Naveed B, Kelly A, Hoshino Y, Hoshino S, Karulf MR,
Rom WN, Weiden MD, Gold JA: Differential role for CD80 and CD86 in
the regulation of the innate immune response in murine polymicrobial
sepsis. PLoS One 2009, 4:e6600.
14. Wisnoski N, Chung CS, Chen Y, Huang X, Ayala A: The contribution of CD4
+ CD25+ T-regulatory-cells to immune suppression in sepsis. Shock 2007,
27:251-257.
15. Pillay J, Kamp VM, van Hoffen E, Visser T, Tak T, Lammers JW, Ulfman LH,
Leenen LP, Pickkers P, Koenderman L: A subset of neutrophils in human
systemic inflammation inhibits T cell responses through Mac-1. J Clin
Invest 2012, 122:327-336.
16. Venet F, Chung CS, Kherouf H, Geeraert A, Malcus C, Poitevin F, Bohe J,
Lepape A, Ayala A, Monneret G: Increased circulating regulatory T cells
(CD4(+)CD25 (+)CD127 (-)) contribute to lymphocyte anergy in septic
shock patients. Intensive Care Med 2009, 35:678-686.
17. Venet F, Chung C-S, Monneret G, Huang X, Horner B, Garber M, Ayala A:
Regulatory T cell populations in sepsis and trauma. J Leukoc Biol 2008,
83:523-535.
18. Gabrilovich DI, Nagaraj S: Myeloid-derived suppressor cells as regulators
of the immune system. 2009, 9:162-174.
19. Delano MJ, Scumpia PO, Weinstein JS, Coco D, Nagaraj S, Kelly-Scumpia KM,
O’Malley KA, Wynn JL, Antonenko S, Al-Quran SZ, Swan R, Chung CS,
Atkinson MA, Ramphal R, Gabrilovich DI, Reeves WH, Ayala A, Phillips J,
Laface D, Heyworth PG, Clare-Salzler M, Moldawer LL: MyD88-dependent
expansion of an immature GR-1(+)CD11b(+) population induces T cell
suppression and Th2 polarization in sepsis. J Exp Med 2007,
204:1463-1474.
20. Boomer JS, To K, Chang KC, Takasu O, Osborne DF, Walton AH, Bricker TL,
Jarman SD, Kreisel D, Krupnick AS, Srivastava A, Swanson PE, Green JM,
Hotchkiss RS: Immunosuppression in patients who die of sepsis and
multiple organ failure. JAMA 2011, 306:2594-2605.
21. Moskophidis D, Lechner F, Pircher H, Zinkernagel RM: Virus persistence in
acutely infected immunocompetent mice by exhaustion of antiviral
cytotoxic effector T cells. Nature 1993, 362:758-761.
22. Robinson HL: T cells versus HIV-1: fighting exhaustion as well as escape.
Nat Immunol 2003, 4:12-13.
23. Fuller MJ, Khanolkar A, Tebo AE, Zajac AJ: Maintenance, loss, and
resurgence of T cell responses during acute, protracted, and chronic
viral infections. J Immunol 2004, 172:4204-4214.
24. Urbani S, Amadei B, Tola D, Massari M, Schivazappa S, Missale G, Ferrari C:
PD-1 expression in acute hepatitis C virus (HCV) infection is associated
with HCV-specific CD8 exhaustion. J Virol 2006, 80:11398-11403.
25. Kim PS, Ahmed R: Features of responding T cells in cancer and chronic
infection. Curr Opin Immunol 2010, 22:223-230.
26. Yi JS, Cox MA, Zajac AJ: T-cell exhaustion: characteristics, causes and
conversion. Immunology 2010, 129:474-481.
27. Day CL, Kaufmann DE, Kiepiela P, Brown JA, Moodley ES, Reddy S,
Mackey EW, Miller JD, Leslie AJ, DePierres C, Mncube Z, Duraiswamy J,
Zhu B, Eichbaum Q, Altfeld M, Wherry EJ, Coovadia HM, Goulder PJ,
Klenerman P, Ahmed R, Freeman GJ, Walker BD: PD-1 expression on HIV-
specific T cells is associated with T-cell exhaustion and disease
progression. Nature 2006, 443:350-354.
28. Freeman GJ, Wherry EJ, Ahmed R, Sharpe AH: Reinvigorating exhausted
HIV-specific T cells via PD-1-PD-1 ligand blockade. J Exp Med 2006,
203:2223-2227.
29. Mumprecht S, Schurch C, Schwaller J, Solenthaler M, Ochsenbein AF:
Programmed death 1 signaling on chronic myeloid leukemia-specific T
cells results in T-cell exhaustion and disease progression. Blood 2009,
114:1528-1536.
30. Watanabe T, Bertoletti A, Tanoto TA: PD-1/PD-L1 pathway and T-cell
exhaustion in chronic hepatitis virus infection. J Viral Hepat 2010,
17:453-458.
31. Levy MM, Fink MP, Marshall JC, Abraham E, Angus D, Cook D, Cohen J,
Opal SM, Vincent JL, Ramsay G: 2001 SCCM/ESICM/ACCP/ATS/SIS
International Sepsis Definitions Conference. Crit Care Med 2003,
31:1250-1256.
32. Andaluz-Ojeda D, Bobillo F, Iglesias V, Almansa R, Rico L, Gandia F, Resino S,
Tamayo E, de Lejarazu RO, Bermejo-Martin JF: A combined score of pro-
and anti-inflammatory interleukins improves mortality prediction in
severe sepsis. Cytokine 2012, 57:332-336.
33. Adib-Conquy M, Cavaillon JM: Compensatory anti-inflammatory response
syndrome. Thromb Haemost 2009, 101:36-47.
34. Schwulst SJ, Muenzer JT, Peck-Palmer OM, Chang KC, Davis CG,
McDonough JS, Osborne DF, Walton AH, Unsinger J, McDunn JE,
Hotchkiss RS: Bim siRNA decreases lymphocyte apoptosis and improves
survival in sepsis. Shock 2008, 30:127-134.
35. Weber SU, Schewe JC, Lehmann LE, Muller S, Book M, Klaschik S, Hoeft A,
Stuber F: Induction of Bim and Bid gene expression during accelerated
apoptosis in severe sepsis. Crit Care 2008, 12:R128.
36. Venet F, Bohe J, Debard AL, Bienvenu J, Lepape A, Monneret G: Both
percentage of gammadelta T lymphocytes and CD3 expression are
reduced during septic shock. Crit Care Med 2005, 33:2836-2840.
37. Venet F, Davin F, Guignant C, Larue A, Cazalis MA, Darbon R, Allombert C,
Mougin B, Malcus C, Poitevin-Later F, Lepape A, Monneret G: Early
assessment of leukocyte alterations at diagnosis of septic shock. Shock
2010, 34:358-363.
38. Ayala A, Perl M, Venet F, Lomas-Neira J, Swan R, Chung CS: Apoptosis in
sepsis: mechanisms, clinical impact and potential therapeutic targets.
Curr Pharm Des 2008, 14:1853-1859.
39. Chung CS, Venet F, Chen Y, Jones LN, Wilson DC, Ayala CA, Ayala A:
Deficiency of Bid protein reduces sepsis-induced apoptosis and
inflammation, while improving septic survival. Shock 2010, 34:150-161.
40. Cheron A, Floccard B, Allaouchiche B, Guignant C, Poitevin F, Malcus C,
Crozon J, Faure A, Guillaume C, Marcotte G, Vulliez A, Monneuse O,
Monneret G: Lack of recovery in monocyte human leukocyte antigen-DR
expression is independently associated with the development of sepsis
after major trauma. Crit Care 2010, 14:R208.
41. Landelle C, Lepape A, Voirin N, Tognet E, BoFhé J, Vanhems P, Monneret G:
Low monocyte human leukocyte antigen-DR is independently
associated with nosocomial infections after septic shock. Intensive Care
Med 2010, 36:1859-1866.
Boomer et al. Critical Care 2012, 16:R112
http://ccforum.com/content/16/3/R112
Page 13 of 14
42. Venet F, Lepape A, Monneret G: Clinical review: flow cytometry
perspectives in the ICU - from diagnosis of infection to monitoring of
injury-induced immune dysfunctions. Crit Care 2011, 15:231.
43. Radziewicz H, Ibegbu CC, Fernandez ML, Workowski KA, Obideen K,
Wehbi M, Hanson HL, Steinberg JP, Masopust D, Eherry EJ, Altman JD,
Rouse BT, Freeman GJ, Ahmed R, Grakoui A: Liver-infiltrating lymphocytes
in chronic human hepatitis C virus infection display an exhausted
phenotype with high levels of PD-1 and low levels of CD127 expression.
J Virol 2007, 81:2545-2553.
44. El-Far M, Halwani R, Said E, Trautmann L, Doroudchi M, Janbazian L,
Fonseca S, van Grevenynghe J, Yassine-Diab B, Sekaly RP, Haddad EK: T-cell
exhaustion in HIV infection. Curr HIV/AIDS Rep 2008, 5:13-19.
45. Fisicaro P, Valdatta C, Massari M, Loggi E, Biasini E, Sacchelli L, Cavallo MC,
Silini EM, Andreone P, Missale G, Ferrari C: Antiviral intrahepatic T-cell
responses can be restored by blocking programmed death-1 pathway in
chronic hepatitis B. Gastroenterology 2010, 138:682-693.
46. Rodrigue-Gervais IG, Rigsby H, Jouan L, Sauve D, Sekaly RP, Willems B,
Lamarre D: Dendritic cell inhibition is connected to exhaustion of CD8+
T cell polyfunctionality during chronic hepatitis C virus infection. J
Immunol 2010, 184:3134-3144.
47. Khaitan A, Unutmaz D: Revisiting immune exhaustion during HIV
infection. Curr HIV/AIDS Rep 2011, 8:4-11.
48. Nolan A, Weiden M, Kelly A, Hoshino Y, Hoshino S, Mehta N, Gold JA: CD40
and CD80/86 act synergistically to regulate inflammation and mortality
in polymicrobial sepsis. Am J Respir Crit Care Med 2008, 177:301-308.
49. Frebel H, Richter K, Oxenius A: How chronic viral infections impact on
antigen-specific T-cell responses. Eur J Immunol 2010, 40:654-663.
50. Wherry EJ: T cell exhaustion. Nat Immunol 2011, 12:492-499.
51. Brahmamdam P, Inoue S, Unsinger J, Chang KC, McDunn JE, Hotchkiss RS:
Delayed administration of anti-PD-1 antibody reverses immune
dysfunction and improves survival during sepsis. J Leukoc Biol 2010,
88:233-240.
52. Guignant C, Lepape A, Huang X, Kherouf H, Denis L, Poitevin F, Malcus C,
Cheron A, Allaouchiche B, Gueyffier F, Ayala A, Monneret G, Venet F:
Programmed death-1 levels correlate with increased mortality,
nosocomial infection and immune dysfunctions in septic shock patients.
Crit Care 2011, 15:R99.
53. Zhang Y, Li J, Lou J, Zhou Y, Bo L, Zhu J, Zhu K, Wan X, Cai Z, Deng X:
Upregulation of programmed death-1 on T cells and programmed
death ligand-1 on monocytes in septic shock patients. Crit Care 2011, 15:
R70.
54. Zhang Y, Zhou Y, Lou J, Li J, Bo L, Zhu K, Wan X, Deng X, Cai Z: PD-L1
blockade improves survival in experimental sepsis by inhibiting
lymphocyte apoptosis and reversing monocyte dysfunction. Crit Care
2010, 14:R220.
55. Freeman GJ, Long AJ, Iwai Y, Bourque K, Chernova T, Nishimura H, Fitz LJ,
Malenkovich N, Okazaki T, Byrne MC, Horton HF, Fouser L, Carter L, Ling V,
Bowman MR, Carreno BM, Collins M, Wood CR, Honjo T: Engagement of
the PD-1 immunoinhibitory receptor by a novel B7 family member leads
to negative regulation of lymphocyte activation. J Exp Med 2000,
192:1027-1034.
56. Barber DL, Wherry EJ, Masopust D, Zhu B, Allison JP, Sharpe AH,
Freeman GJ, Ahmed R: Restoring function in exhausted CD8 T cells
during chronic viral infection. Nature 2006, 439:682-687.
57. Wherry EJ, Ha SJ, Kaech SM, Haining WN, Sarkar S, Kalia V, S
Subramaniam S, Blattman JN, Barber DL, Ahmed R: Molecular signature of
CD8+ T cell exhaustion during chronic viral infection. Immunity 2007,
27:670-684.
58. Scumpia PO, Delano MJ, Kelly KM, O’Malley KA, Efron PA, McAuliffe PF,
Brusko T, Ungaro R, Barker T, Wynn JL, Atkinson MA, Reeves WH, Salzler MJ,
Moldawer LL: Increased natural CD4+CD25+ regulatory T cells and their
suppressor activity do not contribute to mortality in murine
polymicrobial sepsis. J Immunol 2006, 177:7943-7949.
59. Venet F, Pachot A, Debard A-L, Bohe J, Bienvenu J, Lepape A, Powell WS,
Monneret G: Human CD4+CD25+ regulatory T lymphocytes inhibit
lipopolysaccharide-induced monocyte survival through a Fas/Fas ligand-
dependent mechanism. J Immunol 2006, 177:6540-6547.
60. Cavassani KA, Carson WF, Moreira AP, Wen H, Schaller MA, Ishii M,
Lindell DM, Dou Y, Lukacs NW, Keshamouni VG, Hogaboam CM, Kunkel SL:
The post sepsis-induced expansion and enhanced function of regulatory
T cells create an environment to potentiate tumor growth. Blood 2010,
115:4403-4411.
61. Fu Q, Cui N, Yu W, Du C: Percentages of CD4+ T regulatory cells and
HLA-DR expressing monocytes in severe intra-abdominal infections.
Scand J Infect Dis 2010, 42:475-478.
62. Venet F, Pachot A, Debard AL, Bohe J, Bienvenu J, Lepape A, Monneret G:
Increased percentage of CD4+CD25+ regulatory T cells during septic
shock is due to the decrease of CD4+CD25- lymphocytes. Crit Care Med
2004, 32:2329-2331.
doi:10.1186/cc11404
Cite this article as: Boomer et al.: A prospective analysis of lymphocyte
phenotype and function over the course of acute sepsis. Critical Care
2012 16:R112.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Boomer et al. Critical Care 2012, 16:R112
http://ccforum.com/content/16/3/R112
Page 14 of 14
